OncologyPRO is the home of ESMO’s educational and scientific resources

Cytoreductive surgery before chemotherapy offers significantly better survival for recurrent ovarian cancer than chemotherapy alone

Early findings indicate dabrafenib plus trametinib may be active against high- and low-grade glioma carrying the BRAFV600E mutation

Vertebral fractures in women with invasive breast cancer are frequently related to their malignancy

Receiving 20% or more of immune checkpoint inhibitor infusions for advanced melanoma after 16:30 may be linked to poor survival

Patients with advanced BRAF-mutated melanoma may fare better with first-line nivolumab plus ipilimumab than dabrafenib plus trametinib

Patients with early-stage EGFR-positive non-small-cell lung cancer have a high risk of recurrence within 2 years of resection but individual factors may help predict outcomes

Patients with cancer who survive COVID-19 may develop long-term sequelae that can disrupt oncological treatment and shorten survival

89Zr-pembolizumab imaging may help identify advanced melanoma and lung cancer patients who are likely to respond to the PD-1 inhibitor